CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort

Herreros-Villanueva, Marta; Ruiz-Rebollo, Lourdes; Montes, Mario; López, M. Rodríguez; Francisco, M. Alonso de; Cubiella, Joaquín; Iyo, Eduardo; Garabitos, E.; Moneo, Emma Martínez; Martos, Maider; de-Madaria, Enriqué; Martínez‐Arranz, Ibon; García-Cougil, Marta; Iglesias-Gómez, Agueda; Bujanda, Luís

doi:10.1007/s11033-020-05245-5

Cited by 14 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…40 Bolstering this verdict, Herreros-Villanueva et al demonstrated that a pretreatment CA19-9> 500 U/ mL was linked to significantly depreciated resectability rates (18% versus 60%; P<0.05). 41 Regarding the SIRI, our results manifested that SIRI could capably stratify LAPAC patients into two significantly different median PFS and OS groups at a cutoff of 1.8, which appears to be accordant with the historic chemotherapy series and a recently published C-CRT study. 10,35,36 In the first…”

supporting

confidence: 83%

The Prognostic Significance of Novel Pancreas Cancer Prognostic Index in Unresectable Locally Advanced Pancreas Cancers Treated with Definitive Concurrent Chemoradiotherapy

Topkan¹,

Selek²,

Pehlivan³

et al. 2021

JIR

View full text Add to dashboard Cite

Purpose: We evaluated the prognostic quality of the novel pancreas cancer prognostic index (PCPI), a combination of CA 19-9 and systemic inflammation response index (SIRI), on the outcomes of locally advanced pancreas adenocarcinoma (LAPAC) patients who received concurrent chemoradiotherapy (C-CRT). Methods: This retrospective analysis covered 152 unresectable LAPAC patients treated from 2007 to 2019. Receiver operating characteristic (ROC) curve analysis was used to define ideal cutoff thresholds for the pretreatment CA 19-9 and SIRI measurements, individually. The associations between the PCPI groups and progression-free-(PFS) and overall survival (OS) comprised the respective primary and secondary endpoints. Results: The ROC curve analysis distinguished the respective rounded optimal cutoffs at 91 U/m/ L (< versus ≥90) and 1.8 (< versus ≥1.8) for CA 19-9 and SIRI, arranging the study cohort into two significantly different survival groups for each, with resultant four likely groups: Group-1: CA 19-9<90 U/m/L and SIRI<1.8, Group-2: CA 19-9<90 U/m/L but SIRI≥1.8, Group-3: CA 19-9≥90 U/ m/L but SIRI<1.8, and Group-4: CA 19-9≥90 U/m/L and SIRI≥1.8. Since the PFS (P=0.79) and OS (P=0.86) estimates of the groups 2 and 3 were statistically indistinct, we merged them as one group and created the novel three-tiered PCPI:

show abstract

supporting

confidence: 83%

The Prognostic Significance of Novel Pancreas Cancer Prognostic Index in Unresectable Locally Advanced Pancreas Cancers Treated with Definitive Concurrent Chemoradiotherapy

Topkan¹,

Selek²,

Pehlivan³

et al. 2021

JIR

View full text Add to dashboard Cite

show abstract

“…Currently, CA19‐9 is undisputedly the most important surrogate marker of PC biology and has been adopted in most clinical studies and practices. Several papers have validated the cut‐off line of 500 U/mL of CA19‐9 mentioned in the IAP consensus 19‐24 . Moreover, several studies have reported that the change of CA19‐9 could reflect the biological aggressiveness of the tumors after NAT 25‐32 .…”

Section: Biological Factorsmentioning

confidence: 99%

“…Several papers have validated the cut-off line of 500 U/mL of CA19-9 mentioned in the IAP consensus. [19][20][21][22][23][24] Moreover, several studies have reported that the change of CA19-9 could reflect the biological aggressiveness of the tumors after NAT. [25][26][27][28][29][30][31][32] The absolute value of CA19-9 after NAT <72-400 (U/mL) [25][26][27][28] or relative value of 20%-50% decrease of CA19-9 after NAT [30][31][32] were associated with resectability or good prognosis after resection.…”

Section: Biological Factorsmentioning

confidence: 99%

New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery (JSHBPS)

Oba

Chiaro

Satoi

et al. 2021

J Hepato Biliary Pancreat

View full text Add to dashboard Cite

The symposium "New criteria of resectability for pancreatic cancer" was held during the 33nd meeting of the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS) in 2021 to discuss the potential modifications that could be made in the current resectability classification. The meeting focused on setting the foundation for developing a new prognosis-based resectability classification that is based on the tumor biology and the response to neoadjuvant treatment

show abstract

“…39,40 In PDAC, serum CA19-9 levels have been reported to reflect the prognosis of PDAC, 11,41,42 and the link between cutoff values of preoperative serum CA19-9 levels and early postoperative recurrence and poor prognosis was also investigated. 20,30,[43][44][45][46][47] On the other hand, SPan-1 is a cancer-related antigen recognized by a monoclonal antibody prepared using the human PDAC cell line SW1990 as an immune antigen, and it is a high-molecularweight mucin-like protein. 48 Although the sensitivity of SPan-1 for PDAC diagnosis is equivalent to that of CA19-9, SPan-1 is a distinguishing antigen that is synthesized even in Lewis-negative patients.…”

Section: Discussionmentioning

confidence: 99%

Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma

et al. 2021

View full text Add to dashboard Cite

Background Resectable pancreatic ductal adenocarcinoma (R-PDAC) often recurs early after radical resection, which is associated with poor prognosis. Predicting early recurrence preoperatively is useful for determining the optimal treatment. Patients and methods One hundred and seventy-eight patients diagnosed with R-PDAC on computed tomography (CT) imaging and undergoing radical resection at Hirosaki University Hospital from 2005 to 2019 were retrospectively analyzed. Patients with recurrence within 6 months after resection formed the early recurrence (ER) group, while other patients constituted the non-early recurrence (non-ER) group. Early recurrence prediction score (ERP score) was developed using preoperative parameters. Results ER was observed in 45 patients (25.3%). The ER group had significantly higher preoperative CA19-9 (p = 0.03), serum SPan-1 (p = 0.006), and CT tumor diameter (p = 0.01) compared with the non-ER group. The receiver operating characteristic (ROC) curve analysis identified cutoff values for CA19-9 (133 U/mL), SPan-1 (78.2 U/mL), and preoperative tumor diameter (23 mm). When the parameter exceeded the cutoff level, 1 point was given, and the total score of the three factors was defined as the ERP score. The group with an ERP score of 3 had postoperative recurrence-free survival (RFS) of 5.5 months (95% CI 3.02–7.98). Multivariate analysis for ER-related perioperative and surgical factors identified ERP score of 3 [odds ratio (OR) 4.63 (95% CI 1.82–11.78), p = 0.0013] and R1 resection [OR 3.20 (95% CI 1.01–10.17), p = 0.049] as independent predictors of ER. Conclusions For R-PDAC, ER could be predicted by the scoring system using preoperative serum CA19-9 and SPan-1 levels and CT tumor diameter, which may have great significance in identifying patients with poor prognoses and avoiding unnecessary surgery.

show abstract

CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort

Cited by 14 publications

References 24 publications

The Prognostic Significance of Novel Pancreas Cancer Prognostic Index in Unresectable Locally Advanced Pancreas Cancers Treated with Definitive Concurrent Chemoradiotherapy

The Prognostic Significance of Novel Pancreas Cancer Prognostic Index in Unresectable Locally Advanced Pancreas Cancers Treated with Definitive Concurrent Chemoradiotherapy

New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery (JSHBPS)

Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma

Contact Info

Product

Resources

About